Sector Release

31 July 2018, Australia

ASHM welcomes the news that a regimen for treatment of chronic hepatitis C virus (HCV) infection, Maviret (glecaprevir/pibrentasvir), has been approved for listing on the Pharmaceutical Benefits Scheme (PBS).

The PBS listing of a second highly effective pan-genotypic regimen for chronic HCV infection will simplify treatment options for prescribers and patients. The listing will help Australia reach the World Health Organisation target of hepatitis C elimination by 2030.

General Practitioners and Nurse Practitioners can prescribe these regimens under the S85 General Schedule. Everyone living with chronic HCV infection should be considered for antiviral treatment, with two treatment options now available on the PBS of short duration and greater than 95 per cent cure rate across all genotypes of chronic hepatitis C.

Curing hepatitis C substantially reduces the risk of liver cancer and liver failure, reducing mortality from cirrhosis and liver cancer. It can also improve quality of life, including physical, emotional and social health.

 

For more information on Treatment of hepatitis C

 

For more information on hepatitis C training opportunities for health professionals